Genprex, Inc. Files 8-K: Other Events & Financials
Ticker: GNPX · Form: 8-K · Filed: Dec 16, 2024 · CIK: 1595248
Sentiment: neutral
Topics: 8-K, regulatory-filing, financials
Related Tickers: GNPX
TL;DR
Genprex filed an 8-K on 12/16/24 for other events and financials. Stay tuned for updates.
AI Summary
Genprex, Inc. filed an 8-K on December 16, 2024, reporting other events and financial statements. The company, incorporated in Delaware with its principal executive offices in Austin, Texas, operates in the pharmaceutical preparations sector. This filing serves as a current report under the Securities Exchange Act of 1934.
Why It Matters
This 8-K filing provides an update on Genprex, Inc.'s corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status and regulatory compliance.
Risk Assessment
Risk Level: low — This filing is a routine 8-K for reporting events and financial statements, not indicating any immediate operational or financial distress.
Key Numbers
- 001-38244 — SEC File Number (Identifies the company's filing history with the SEC.)
- 90-0772347 — IRS Employer Identification Number (Company's tax identification number.)
Key Players & Entities
- Genprex, Inc. (company) — Registrant
- December 16, 2024 (date) — Date of report
- Austin, Texas (location) — Principal executive offices location
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The provided text does not detail the specific 'Other Events' beyond stating that this item is included in the filing.
What is the primary business of Genprex, Inc. based on its SIC code?
Genprex, Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
When was this 8-K report filed?
This 8-K report was filed on December 16, 2024.
Where are Genprex, Inc.'s principal executive offices located?
Genprex, Inc.'s principal executive offices are located at 3300 Bee Cave Road, #650-227, Austin, TX 78746.
What is the company's jurisdiction of incorporation?
Genprex, Inc. is incorporated in Delaware.
Filing Stats: 1,178 words · 5 min read · ~4 pages · Grade level 13.5 · Accepted 2024-12-16 09:15:09
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share GNPX The Nasdaq Capital Ma
Filing Documents
- gnpx20241205_8k.htm (8-K) — 34KB
- 0001437749-24-037525.txt ( ) — 168KB
- gnpx-20241216.xsd (EX-101.SCH) — 3KB
- gnpx-20241216_def.xml (EX-101.DEF) — 12KB
- gnpx-20241216_lab.xml (EX-101.LAB) — 15KB
- gnpx-20241216_pre.xml (EX-101.PRE) — 12KB
- gnpx20241205_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On December 16, 2024, Genprex, Inc. ("Genprex" or the "Company") issued a press release in which it announced that Genprex has completed the Phase 1 dose escalation portion of the Acclaim-3 clinical trial of Reqorsa Gene Therapy (quaratusugene ozeplasmid) in combination with Genentech's Tecentriq (atezolizumab) as maintenance therapy for patients with extensive stage small cell lung cancer ("ES-SCLC") who developed tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. In addition, the Safety Review Committee ("SRC") has approved the opening of the Phase 2 expansion portion of the trial. Based on full safety data, which showed no dose limiting toxicities, the SRC determined that the Recommended Phase 2 Dose of REQORSA will be 0.12 mg/kg. This was the highest dose level delivered in the Phase 1 portion of the trial. The SRC also recommended the trial advance to the Phase 2 expansion portion of the study, which the Company has now opened for enrollment. The Company also noted that it will be submitting the results of the Phase 1 portion of the study to a clinical meeting and anticipates data presentation in 2025. The Phase 1 dose escalation portion of the trial had two dose groups: 0.09 mg/kg and 0.12 mg/kg. The Company anticipates that the Phase 2 expansion portion will enroll approximately 50 patients at approximately 10 to 15 U.S sites. Patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced. The primary endpoint of the Phase 2 portion is to determine the 18-week progression-free survival rate from the time of the start of maintenance therapy with REQORSA and Tecentriq in patients with ES-SCLC. Patients will also be followed for survival. A Phase 2 futility analysis will be performed after the 25th patient enrolled and treated reaches 18 weeks of follow up. The Acclaim-3 clinical trial has received U.S. Food and Drug Administration ("FDA")
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENPREX, INC. Date: December 16, 2024 By: /s/ Ryan Confer Ryan Confer Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)